Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Tax Provisions (2016 - 2025)

Integra Lifesciences Holdings' Tax Provisions history spans 17 years, with the latest figure at $6.0 million for Q4 2025.

  • For Q4 2025, Tax Provisions rose 93.63% year-over-year to $6.0 million; the TTM value through Dec 2025 reached -$47.0 million, down 316.43%, while the annual FY2025 figure was -$47.0 million, 316.43% down from the prior year.
  • Tax Provisions for Q4 2025 was $6.0 million at Integra Lifesciences Holdings, up from -$1.4 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $21.9 million in Q1 2021 and bottomed at -$46.9 million in Q2 2025.
  • The 5-year median for Tax Provisions is $5.8 million (2023), against an average of $1.7 million.
  • The largest annual shift saw Tax Provisions surged 867.46% in 2021 before it crashed 1584.48% in 2025.
  • A 5-year view of Tax Provisions shows it stood at $6.4 million in 2021, then soared by 75.89% to $11.3 million in 2022, then fell by 19.87% to $9.0 million in 2023, then crashed by 65.58% to $3.1 million in 2024, then skyrocketed by 93.63% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Tax Provisions are $6.0 million (Q4 2025), -$1.4 million (Q3 2025), and -$46.9 million (Q2 2025).